ArticleScientific reports2021
A new prognostic score for predicting survival in patients treated with robotic stereotactic radiotherapy for brain metastases.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Prediction of the treatment response and local failure of patients with brain metastasis treated with stereotactic radiosurgery using machine learning: A systematic review and meta-analysis.Neurosurgical review · 2024Pooled it
- Prospective registry study of single-isocenter dynamic conformal Arc SRS for multiple brain metastases.Scientific reports · 2025Article
- Effect of gamma knife stereotactic radiotherapy on the hematological system in patients with advanced lung cancer and its therapeutic effect.American journal of cancer research · 2025Article
- Prediction of brain metastasis development with DNA methylation signatures.Nature medicine · 2025Article
- Article
- Analysis of prognostic factors and the role of epilepsy in neurosurgical patients with brain metastases.Surgical neurology international · 2024Article
- Concomitant radiosurgical and targeted oncological treatment improves the outcome of patients with brain metastases from gastrointestinal cancer.Radiation oncology (London, England) · 2023Article
- Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases.ESMO open · 2023Article
- Optimizing treatment of brain metastases in an era of novel systemic treatments: a single center consecutive series.Journal of neuro-oncology · 2023Article
- Stratified assessment of an FDA-cleared deep learning algorithm for automated detection and contouring of metastatic brain tumors in stereotactic radiosurgery.Radiation oncology (London, England) · 2023Article
- Association between red blood cell distribution width and mortality in patients with metastatic brain tumors: A retrospective single-center cohort study.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study aimed to analyze potential prognostic factors in patients treated with robotic radiosurgery for brain metastases irrespective of primary tumor location and create a simple prognostic score that can be used without a full diagnostic workup. A retrospective analysis of 142 patients with 1-9 brain metastases treated with stereotactic radiosurgery (1-4 fractions) was performed. Volumes of all lesions were calculated using linear dimensions of the tumors (CC, LR, AP) and 4/3*π*(CC/2)*(LR/2)*(AP/2) formula. Kaplan-Meier method and log-rank test were used to analyze survival. Variables significantly associated with overall survival in univariate analysis were included in Cox multivariate analysis. The validity of the model was tested with the bootstrap method. Variables from the final model were used to construct a new prognostic index by assigning points according to the impact of a specific variable on overall survival. In the multivariate analysis, four factors: Karnofsky Performance Status (p = 0.000068), number of brain metastases (p = 0.019), volume of the largest lesion (p = 0.0037), and presence of extracerebral metastases (p = 0.0017), were independent predictors of survival. Total scores ranged from 0 to 12 points, and patients were divided into four groups based on median survival of each subgroup: 0-1 points-18.8 months, 2-3 points-16.9 months, 4-5 points-5.6 months, and ≥ 6 points-4.9 months (p < 0.001). The new prognostic index is simple to calculate. It has a strong prognostic value in a heterogeneous population of patients with a various number of brain metastases, but its value requires confirmation in another cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.